Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05776017Phase 1Unknown

MSP3-CRM-Vac4All/ Alhydrogel® Vaccine

Role: lead

NCT05197751Phase 1Unknown

MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine

Role: lead

NCT01341704Phase 2Completed

Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa

Role: lead

NCT01605786Phase 1Unknown

Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)

Role: lead

All 4 trials loaded